Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655928 | 0.86 | ATR (0.53) | RETKDRPIK3CDATRBTK | |
| SCHEMBL23917469 | 0.85 | PIK3CD (0.45) | TGFBR1RETKDRSRCPIK3CD | |
| SCHEMBL16655542 | 0.83 | RET (0.51) | RETKDRPIK3CDATRBTK | |
| SCHEMBL16655774 | 0.83 | ATR (0.53) | RETKDRPIK3CDATRBTK | |
| SCHEMBL16655754 | 0.81 | RET (0.51) | RETKDRPIK3CDATRBTK | |
| SCHEMBL23917246 | 0.79 | RET (0.37) | RETFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL23917247 | 0.78 | RET (0.49) | TGFBR1RETKDRSRCPIK3CD | |
| SCHEMBL23917204 | 0.75 | RET (0.49) | TGFBR1RETKDRSRCPIK3CD | |
| SCHEMBL16655734 | 0.74 | RET (0.43) | RETKDRPIK3CDBTK | |
| SCHEMBL16655326 | 0.73 | PIK3CD (0.56) | RETKDRPIK3CDATRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | TGFBR1 3390/4885RET 753/4885KDR 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.